Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE)
- PMID: 24561113
- DOI: 10.1016/j.amjmed.2014.02.009
Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE)
Abstract
Background: Current guidelines recommend early oral beta-blocker administration in the management of acute coronary syndromes for patients who are not at high risk of complications.
Methods: Data from patients enrolled between 2000 and 2007 in the Global Registry of Acute Coronary Events (GRACE) were used to evaluate hospital outcomes in 3 cohorts of patients admitted with ST-elevation myocardial infarction, based on beta-blocker use (early [first 24 hours] intravenous (IV) [± oral], only early oral, or delayed [after first 24 hours]).
Results: Among 13,110 patients with ST-elevation myocardial infarction, 21% received any early IV beta-blockers, 65% received only early oral beta-blockers, and 14% received delayed (>24 hours) beta-blockers. Higher systolic blood pressure, higher heart rate, and chronic beta-blocker use were independent predictors of early beta-blocker use. Early beta-blocker use was less likely in older patients, patients with moderate to severe left ventricular dysfunction, and in those presenting with inferior myocardial infarction or Killip class II or III heart failure. IV beta-blocker use and delayed beta-blocker use were associated with higher rates of cardiogenic shock, sustained ventricular fibrillation/ventricular tachycardia, and acute heart failure, compared with oral beta-blocker use. In-hospital mortality was increased with IV beta-blocker use (propensity score adjusted odds ratio, 1.41; 95% confidence interval, 1.03-1.92) but significantly reduced with delayed beta-blocker administration (propensity adjusted odds ratio, 0.44; 95% confidence interval, 0.26-0.74).
Conclusions: Early beta-blocker use is common in patients presenting with ST-elevation myocardial infarction, with oral administration being the most prevalent. Oral beta-blockers were associated with a decrease in the risk of cardiogenic shock, ventricular arrhythmias, and acute heart failure. However, the early receipt of any form of beta-blockers was associated with an increase in hospital mortality.
Keywords: Clinical outcomes; Intravenous beta-blockers; Oral beta-blockers; ST-elevation myocardial infarction.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Patterns of use and potential impact of early beta-blocker therapy in non-ST-elevation myocardial infarction with and without heart failure: the Global Registry of Acute Coronary Events.Am Heart J. 2006 Dec;152(6):1015-21. doi: 10.1016/j.ahj.2006.08.024. Am Heart J. 2006. PMID: 17161045
-
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).Am J Cardiol. 2008 Dec 1;102(11):1427-32. doi: 10.1016/j.amjcard.2008.07.033. Epub 2008 Sep 11. Am J Cardiol. 2008. PMID: 19026290
-
Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction.Am J Med. 2007 Aug;120(8):685-92. doi: 10.1016/j.amjmed.2007.04.016. Am J Med. 2007. PMID: 17679127
-
A review and meta-analysis of studies on the effect and timing of β-blocker administration in patients with ST-segment elevation myocardial infarction.Hosp Pract (1995). 2010 Nov;38(4):63-8. doi: 10.3810/hp.2010.11.341. Hosp Pract (1995). 2010. PMID: 21068528 Review.
-
Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials.Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):469-477. doi: 10.1177/2048872619830609. Epub 2019 Feb 14. Eur Heart J Acute Cardiovasc Care. 2020. PMID: 30759994 Free PMC article. Review.
Cited by
-
Influence of the previous use of β-blockers on the early clinical course of acute coronary syndromes.Intern Emerg Med. 2015 Oct;10(7):831-7. doi: 10.1007/s11739-015-1251-3. Epub 2015 May 20. Intern Emerg Med. 2015. PMID: 25990485
-
Impact of Bisoprolol on Ventricular Arrhythmias in Experimental Myocardial Infarction.Chonnam Med J. 2021 May;57(2):132-138. doi: 10.4068/cmj.2021.57.2.132. Epub 2021 May 24. Chonnam Med J. 2021. PMID: 34123741 Free PMC article.
-
Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol.Medicina (Kaunas). 2021 Sep 30;57(10):1047. doi: 10.3390/medicina57101047. Medicina (Kaunas). 2021. PMID: 34684084 Free PMC article.
-
Atrioventricular block after reperfusion: A reflection on early beta-blocker therapy for acute myocardial infarction.Anatol J Cardiol. 2017 Dec;18(6):438-439. doi: 10.14744/AnatolJCardiol.2017.8159. Anatol J Cardiol. 2017. PMID: 29256884 Free PMC article. No abstract available.
-
Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction.ESC Heart Fail. 2021 Feb;8(1):344-355. doi: 10.1002/ehf2.13079. Epub 2020 Dec 1. ESC Heart Fail. 2021. PMID: 33259148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical